Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | FABP4 | P15090 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | XBP1 | P17861 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | S100A9 | P06702 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6542083 | 0.86 | UTS2R (0.53) | UTS2RALDH1A1LMNAPOLBHTT | |
| SCHEMBL6542669 | 0.84 | UTS2R (0.53) | UTS2RALDH1A1LMNAPOLBHTT | |
| SCHEMBL6542118 | 0.82 | UTS2R (0.57) | UTS2RALDH1A1LMNAPOLBHTT | |
| SCHEMBL6541903 | 0.79 | LMNA (0.51) | UTS2RALDH1A1LMNAPOLBHTT | |
| SCHEMBL6541965 | 0.78 | UTS2R (0.52) | UTS2RALDH1A1LMNAPOLBHTT | |
| SCHEMBL6542637 | 0.78 | UTS2R (0.52) | UTS2RALDH1A1LMNAPOLBHTT | |
| SCHEMBL6177410 | 0.78 | UTS2R (0.74) | UTS2RALDH1A1LMNAHTTKMT2A | |
| SCHEMBL6542613 | 0.78 | UTS2R (0.52) | UTS2RALDH1A1LMNAPOLBHTT | |
| SCHEMBL6542543 | 0.78 | LMNA (0.56) | UTS2RALDH1A1LMNAPOLBHTT | |
| SCHEMBL6542898 | 0.78 | UTS2R (0.51) | UTS2RALDH1A1LMNAPOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1248607-A4 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-10-06 | — | — | EP | claimed |
| US-20030100580-A1 | Urotensin-II receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-05-29 | — | — | US | claimed |
| EP-1248607-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-10-16 | — | — | EP | claimed |
| WO-2001045694-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-06-28 | — | — | WO | claimed |
| US-20030100580-A1 | Urotensin-II receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100580-A1 | Urotensin-II receptor antagonists | UTS2R, TMPRSS4, PLAUR | UTS2R 1/4885ALDH1A1 4452/4885LMNA 4591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.